ArticleClinical pharmacokinetics2023

Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer.

Neang S Ly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.